Large-vessel vasculitis
D Pugh, M Karabayas, N Basu, MC Cid… - Nature Reviews …, 2021 - nature.com
Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …
The Th17 pathway in vascular inflammation: culprit or consort?
M Robert, P Miossec, A Hot - Frontiers in Immunology, 2022 - frontiersin.org
The involvement of IL-17A in autoimmune and inflammatory diseases has prompted the
development of therapeutic strategies to block the Th17 pathway. Promising results came …
development of therapeutic strategies to block the Th17 pathway. Promising results came …
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis
C Campochiaro, A Tomelleri, S Sartorelli… - Seminars in Arthritis and …, 2020 - Elsevier
Objective We retrospectively investigated drug retention rate (DRR) and reasons for
discontinuation of seven biologic disease-modifying anti-rheumatic drugs (bDMARDs) in …
discontinuation of seven biologic disease-modifying anti-rheumatic drugs (bDMARDs) in …
[PDF][PDF] S2K-Leitlinie: management der Großgefäßvaskulitiden
JH Schirmer, PM Aries, K Balzer, P Berlit, TA Bley… - Z Rheumatol, 2020 - academia.edu
Die Leitlinie wurde unter Berücksichtigung anderer zu diesem Thema publizierter Leitlinien
wie den aktualisierten Empfehlungen der European League Against Rheumatism (EULAR) …
wie den aktualisierten Empfehlungen der European League Against Rheumatism (EULAR) …
S2k guidelines: management of large-vessel vasculitis
JH Schirmer, PM Aries, K Balzer, P Berlit… - Zeitschrift für …, 2020 - Springer
Die Leitlinie wurde unter Berücksichtigung anderer zu diesem Thema publizierter Leitlinien
wie den aktualisierten Empfehlungen der European League Against Rheumatism (EULAR) …
wie den aktualisierten Empfehlungen der European League Against Rheumatism (EULAR) …
Current and emerging therapies in large-vessel vasculitis
TA Kermani, B Dasgupta - Rheumatology, 2018 - academic.oup.com
GCA shares many clinical features with PMR and Takayasu arteritis. The current mainstay of
therapy for all three conditions is glucocorticoid therapy. Given the chronic, relapsing nature …
therapy for all three conditions is glucocorticoid therapy. Given the chronic, relapsing nature …
Off‐label uses of ustekinumab
L Ye, Z Wu, C Li, X Zhao, M Wan… - Dermatologic …, 2022 - Wiley Online Library
Ustekinumab (brand name Stelara®) is a human interleukin‐12 and‐23 antagonist and has
been indicated for the treatments of moderate to severe plaque psoriasis, psoriatic arthritis …
been indicated for the treatments of moderate to severe plaque psoriasis, psoriatic arthritis …
Extended-release tofacitinib improves refractory Takayasu's arteritis
CR Wang, YS Tsai, YW Liu, YH Li - Scandinavian Journal of …, 2022 - Taylor & Francis
Takayasu's arteritis (TAK), a chronic inflammatory disorder mainly affecting the aorta and its
major branches, can cause vascular injury with thickened walls, luminal stenosis …
major branches, can cause vascular injury with thickened walls, luminal stenosis …
[HTML][HTML] Ustekinumab
M Colquhoun, AK Kemp - 2021 - europepmc.org
Objectives: Explain the mechanism of action of ustekinumab. Describe the indications for the
use of ustekinumab. Review the potential adverse event that can accompany ustekinumab …
use of ustekinumab. Review the potential adverse event that can accompany ustekinumab …
Central and Peripheral Nervous System Complications of Vasculitis Syndromes from Pathology to Bedside: Part 2—Peripheral Nervous System
G Mansueto, G Lanza, J Falleti, P Orabona… - Current Neurology and …, 2023 - Springer
Abstract Purpose of Review Peripheral nervous system vasculitides (PNSV) are a
heterogeneous group of disorders with a clinical subset that may differ in prognosis and …
heterogeneous group of disorders with a clinical subset that may differ in prognosis and …